Amphastar [AMPH] vs BioCryst [BCRX] Detailed Stock Comparison
Amphastar
NASDAQ
Loading...
BioCryst
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Amphastar wins in 12 metrics, BioCryst wins in 7 metrics, with 0 ties. Amphastar appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Amphastar | BioCryst | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 7.72 | -19.41 | BioCryst |
| Price-to-Book Ratio | 1.35 | -4.15 | BioCryst |
| Debt-to-Equity Ratio | 86.86 | -1.97 | BioCryst |
| PEG Ratio | 4.87 | -215.00 | BioCryst |
| EV/EBITDA | 5.63 | 39.98 | Amphastar |
| Profit Margin (TTM) | 19.38% | -6.41% | Amphastar |
| Operating Margin (TTM) | 21.87% | 18.23% | Amphastar |
| EBITDA Margin (TTM) | 21.87% | 18.23% | Amphastar |
| Return on Equity | 19.90% | 18.68% | Amphastar |
| Return on Assets (TTM) | 7.60% | -18.12% | Amphastar |
| Free Cash Flow (TTM) | $172.35M | $-53.14M | Amphastar |
| 1-Year Return | -49.47% | 9.44% | BioCryst |
| Price-to-Sales Ratio (TTM) | 1.37 | 3.24 | Amphastar |
| Enterprise Value | $1.40B | $2.34B | BioCryst |
| EV/Revenue Ratio | 1.91 | 4.20 | Amphastar |
| Gross Profit Margin (TTM) | 49.99% | 98.29% | BioCryst |
| Revenue per Share (TTM) | $15 | $3 | Amphastar |
| Earnings per Share (Diluted) | $2.76 | $-0.18 | Amphastar |
| Beta (Stock Volatility) | 0.76 | 1.10 | Amphastar |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Amphastar vs BioCryst Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Amphastar | 10.13% | 3.20% | -5.42% | -11.50% | -33.21% | -40.54% |
| BioCryst | -0.48% | 2.58% | -4.68% | -17.16% | -4.24% | 6.64% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Amphastar | -49.47% | -31.53% | 6.44% | 47.88% | 106.19% | 106.19% |
| BioCryst | 9.44% | -42.96% | 93.74% | -28.51% | 67.67% | 21.19% |
Performance & Financial Health Analysis: Amphastar vs BioCryst
| Metric | AMPH | BCRX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.00B | $1.81B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 374,219 | 4,481,040 |
| 90 Day Avg. Volume | 471,943 | 3,738,173 |
| Last Close | $23.81 | $8.31 |
| 52 Week Range | $20.39 - $53.96 | $6.02 - $11.31 |
| % from 52W High | -55.87% | -26.53% |
| All-Time High | $67.66 (Aug 07, 2023) | $37.25 (Mar 06, 2000) |
| % from All-Time High | -64.81% | -77.69% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.01% | 0.49% |
| Quarterly Earnings Growth | -0.41% | 0.49% |
| Financial Health | ||
| Profit Margin (TTM) | 0.19% | -0.06% |
| Operating Margin (TTM) | 0.22% | 0.18% |
| Return on Equity (TTM) | 0.20% | 0.19% |
| Debt to Equity (MRQ) | 86.86 | -1.97 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $15.76 | $-2.16 |
| Cash per Share (MRQ) | $5.03 | $1.41 |
| Operating Cash Flow (TTM) | $193.17M | $-42,506,000 |
| Levered Free Cash Flow (TTM) | $-3,711,000 | $-69,720,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Amphastar vs BioCryst
| Metric | AMPH | BCRX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 7.72 | -19.41 |
| Forward P/E | 4.87 | -215.00 |
| PEG Ratio | 4.87 | -215.00 |
| Price to Sales (TTM) | 1.37 | 3.24 |
| Price to Book (MRQ) | 1.35 | -4.15 |
| Market Capitalization | ||
| Market Capitalization | $1.00B | $1.81B |
| Enterprise Value | $1.40B | $2.34B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.91 | 4.20 |
| Enterprise to EBITDA | 5.63 | 39.98 |
| Risk & Other Metrics | ||
| Beta | 0.76 | 1.10 |
| Book Value per Share (MRQ) | $15.76 | $-2.16 |
Financial Statements Comparison: Amphastar vs BioCryst
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AMPH | BCRX |
|---|---|---|
| Revenue/Sales | $170.53M | $145.53M |
| Cost of Goods Sold | $85.28M | $4.57M |
| Gross Profit | $85.25M | $140.97M |
| Research & Development | $20.10M | $37.27M |
| Operating Income (EBIT) | $37.29M | $21.23M |
| EBITDA | $52.36M | $24.58M |
| Pre-Tax Income | $30.86M | $758,000 |
| Income Tax | $5.58M | $726,000 |
| Net Income (Profit) | $25.29M | $32,000 |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AMPH | BCRX |
|---|---|---|
| Cash & Equivalents | $182.78M | $105.19M |
| Total Current Assets | $587.96M | $409.98M |
| Total Current Liabilities | $199.05M | $139.86M |
| Long-Term Debt | $644.56M | $792.12M |
| Total Shareholders Equity | $751.28M | $-451.93M |
| Retained Earnings | $594.07M | $-1.77B |
| Property, Plant & Equipment | $46.16M | $19.58M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AMPH | BCRX |
|---|---|---|
| Operating Cash Flow | $16.18M | $21.14M |
| Capital Expenditures | $-10.70M | $-143,000 |
| Free Cash Flow | $24.38M | $-27.66M |
| Debt Repayment | $-38,000 | $-516,000 |
| Common Stock Repurchase | $-11.00M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | AMPH | BCRX |
|---|---|---|
| Shares Short | 4.01M | 26.78M |
| Short Ratio | 7.91 | 7.80 |
| Short % of Float | 0.17% | 0.13% |
| Average Daily Volume (10 Day) | 374,219 | 4,481,040 |
| Average Daily Volume (90 Day) | 471,943 | 3,738,173 |
| Shares Outstanding | 47.62M | 208.54M |
| Float Shares | 35.99M | 207.67M |
| % Held by Insiders | 0.24% | 0.01% |
| % Held by Institutions | 0.73% | 0.85% |
Dividend Analysis & Yield Comparison: Amphastar vs BioCryst
| Metric | AMPH | BCRX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |